

Review Article



Precision Medicine and Cardiovascular Health: Insights from Mendelian Randomization Analyses

Wes Spiller , MSc¹, Keum Ji Jung , PhD², Ji-Young Lee , PhD², and Sun Ha Jee , PhD²

¹Department of Population Health Sciences, University of Bristol, Bristol, UK

²Department of Epidemiology and Health Promotion, Institute for Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, Korea



Received: Sep 17, 2019

Accepted: Sep 23, 2019

Correspondence to

Sun Ha Jee, PhD

Department of Epidemiology and Health Promotion, Institute for Health Promotion, Graduate School of Public Health, Yonsei University, 50-1, Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.

E-mail: jsunha@yuhs.ac


Copyright © 2020. The Korean Society of Cardiology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


ORCID iDs

Wes Spiller 


<https://orcid.org/0000-0002-8169-5531>

Keum Ji Jung 

<https://orcid.org/0000-0003-4993-0666>

Ji-Young Lee 

<https://orcid.org/0000-0002-7784-1401>

Sun Ha Jee 

<https://orcid.org/0000-0001-9519-3068>

Funding

Wes Spiller is supported by a Wellcome Trust studentship (108902/B/15/Z). Sun Ha Jee is funded by a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI14C2686).

ABSTRACT

Cardiovascular disease (CVD) is considered a primary driver of global mortality and is estimated to be responsible for approximately 17.9 million deaths annually. Consequently, a substantial body of research related to CVD has developed, with an emphasis on identifying strategies for the prevention and effective treatment of CVD. In this review, we critically examine the existing CVD literature, and specifically highlight the contribution of Mendelian randomization analyses in CVD research. Throughout this review, we assess the extent to which research findings agree across a range of studies of differing design within a triangulation framework. If differing study designs are subject to non-overlapping sources of bias, consistent findings limit the extent to which results are merely an artefact of study design. Consequently, broad agreement across differing studies can be viewed as providing more robust causal evidence in contrast to limiting the scope of the review to a single specific study design. Utilising the triangulation approach, we highlight emerging patterns in research findings, and explore the potential of identified risk factors as targets for precision medicine and novel interventions.

Keywords: Mendelian randomization analysis; Precision medicine; Triangulation; Cardiovascular diseases

INTRODUCTION

Cardiovascular disease (CVD) is a leading cause of mortality and morbidity worldwide, contributing to over 17.6 million deaths annually.¹⁾ However, while the proportion of CVD cases has grown by approximately 14.5% globally over the period 2006–2016, this does not reflect a uniform increase in CVD cases geographically. For example, in contrast to the global increase in CVD cases, Organisation for Economic Co-operation and Development (OECD) member countries have shown an average reduction in CVD related mortality by approximately 42% from 1985–2005.²⁾ Korea specifically has shown a faster decrease in CVD mortality than the OECD average at 182 cases per 100,000 population.²⁾ Many explanations for diverging trends in CVD incidence exist, ranging from differing intervention strategies on modifiable risk factors such as smoking, to differing country-specific configurations of non-modifiable risk factors, such as age or genetic predisposition. These patterns have served to

Conflict of Interest

The authors have no financial conflicts of interest.

Author Contributions

Conceptualization: Jung KJ; Investigation: Jung KJ; Methodology: Lee JY, Jee SH; Supervision: Jee SH; Writing - original draft: Spiller W, Jee SH; Writing - review & editing: Spiller W, Jung KJ, Lee JY, Jee SH.

motivate CVD research, with the primary aim of identifying novel and effective targets for the clinical treatment and prevention of CVD.

The proliferation of studies including large-scale genetic data has had a profound impact upon CVD related research. Through genome-wide association study (GWAS), conducted with increasingly large sample sizes, it has been possible to identify candidate genetic variants associated with CVD related illness. Further, the emergence of Mendelian randomization (MR) approaches has presented the possibility for causal relationships to be estimated whilst controlling for residual confounding, a persistent concern in observational analyses. These developments have, in tandem, allowed for novel genetic drug targets to be identified and previously identified risk factors to be re-evaluated from differing perspectives. Genetic studies can be valuable in identifying groups predisposed to health outcomes, whilst MR focuses on estimating the causal contribution of life-long exposure to modifiable risk factors.

In many cases studies aim to elucidate the causal mechanisms underlying CVD, highlighting key aspects of the aetiology of CVD related illness which are suitable for intervention. However, owing to strengths and limitations unique to a given study design, it is often difficult to infer causality based on a single study. This motivates the triangulation-based approach to evidence evaluation, proposed by Lawlor et al.,³⁾ which focuses upon agreement in research findings across studies of varying design. If each study design is subject to differing and unrelated forms of potential bias, substantial agreement in research findings across multiple different studies limits the extent to which findings are the result of bias specific to study design.³⁾ Alternatively, observed differences in research findings can indicate the presence of one or more study-specific features which introduce bias into estimates of association.

In this review we critically evaluate the contribution of studies using observational, genetic, and MR study designs within a triangulation framework, exploring the extent to which patterns are observable with respect to identified risk factors for CVD. In particular, we focus upon the role of MR as a novel source of evidence in CVD research and highlight recent developments in the MR literature which warrant further attention. Finally, we link identified risk factors to the development of precision medicine and novel interventions, highlighting key areas which warrant attention in future CVD research.

CARDIOVASCULAR DISEASE AND THE KOREAN POPULATION

CVD represents a range of illnesses related to cardiovascular health including, but not limited to, hypertension, coronary heart disease (CHD), myocardial infarction (MI), heart failure, and stroke. It has been estimated that approximately 80% of CVD cases are preventable, and a wide range of potential modifiable risk factors for CVD have been previously identified.⁴⁾ Historically, studies identifying CVD related risk factors have utilised samples of European ancestry, making it difficult to generalise research findings internationally. However, the emergence of large-scale cohort studies in non-European populations provides an opportunity for replication in populations of differing ancestry. One such study is the Korean Cancer Prevention Study-II (KCPS-II) Biobank, which as a blood-based cohort with long-term follow-up provides valuable information with respect to modifiable risk factors and genetic determinants of CVD.⁵⁾

The Korean Cancer Prevention Study-II Biobank

KCPS-II Biobank is a large blood-based cohort study comprised of 156,701 participants (94,840 men and 61,861 women) recruited from 18 health promotion centres across South Korea from 2004–2013.⁵⁾ Participants underwent a health assessment including a self-complete questionnaire and medical examination, collecting data related to social status, health status, behaviour, physiology, and serum measures. Long-term follow-up; specifically, for cancer incidence, hospital admissions, and cause-specific mortality, was obtained using linkage to subsequent medical examinations at health promotion centres across South Korea. Further details available in a previously published cohort profile.⁵⁾

The inclusion of blood-based measures presents a valuable opportunity to elucidate the causal mechanisms behind CVD in the Korean population. Such measures allow for lipid concentrations, such as low-density lipoprotein cholesterol (LDL-C), to be examined within the context of CVD, and crucially, subsequent genotyping of KCPS-II Biobank participants allows for genetic determinants of CVD to be evaluated. The availability of genetic data in a non-European sample allows for candidate genetic variants implicated in CVD incidence to be re-evaluated and facilitates the application of MR approaches. Throughout this review, we relate key findings to the Korean population where available and highlight emerging research relevant to East Asia.

OBSERVATIONAL ANALYSES OF CARDIOVASCULAR DISEASE

Previous research has drawn attention to several risk factors for CVD related illness identified using observational analyses. Such studies include large-scale population based studies, in particular the Framingham Heart Study, the Cardiovascular research using LInked Bespoke studies and Electronic health Records (CALIBER) programme, and studies using Kaiser-Permanente data.⁶⁻¹⁰⁾ Further details regarding each study are provided in the web appendix.

Lipids

There is a substantial body of research linking serum lipids to the onset of CVD.¹¹⁻¹³⁾ Observed changes in lipid levels arising from migration and interventions, and the subsequent impact on incidence of CVD initially suggested that total serum lipid levels could serve as an indicator of CVD risk.¹⁴⁾¹⁵⁾ Subsequent observational analyses have shown evidence of a positive association between LDL-C and CVD.¹⁶⁻¹⁸⁾ However, the relationship of high-density lipoprotein cholesterol (HDL-C) and triglycerides with respect to CVD remains controversial. Initially, HDL-C was found to be protective against CVD; however, subsequent studies have highlighted that this may not universally be the case.¹⁹⁾²⁰⁾ Rather, functionality of high-density lipoprotein may be more important, with high levels of HDL-C becoming pro-inflammatory only under specific conditions.²¹⁾²²⁾ Triglycerides have also been found to be a useful biomarker for CVD, but this could likely be due to their association with causal risk factors such as apo CIII.²³⁾

These observed relationships between lipids and CVD have largely been replicated in East Asia and Korea specifically.¹⁴⁾²⁴⁾ Using data from KCPS-II Biobank Jung et al found LDL-C to be a strong predictor of stroke, warranting inclusion in a general risk score comprised of several traditional risk factors.²⁵⁾ Using a similar approach, Jee et al.²⁶⁾ found LDL-C to be highly predictive of CVD using data from the Korean Heart Study. Strong associations were also found for HDL-C and triglycerides, adjusting for LDL-C.

Alcohol consumption

Alcohol has been implicated as a risk factor for CVD related illness for decades. In 1974, Klatsky et al.²⁷⁾ identified a positive association between alcohol consumption and MI using data from the Kaiser Permanente Health Plan in California. This case-control study also found alcohol to be a risk factor independent of smoking status.²⁷⁾ However, whilst alcohol appears to be causally linked with many forms of CVD, the range of associations has been shown to be diverse across CVD related illness.²⁸⁾ Subsequent analyses using electronic health records from CALIBER have found heavy drinking to be associated with increased risk of coronary death and ischaemic stroke, whilst participants not consuming alcohol appear to be at greater risk for angina, MI, and ischaemic stroke.⁸⁾ Such findings seem to suggest a protective effect of alcohol in low doses, though such an interpretation remains highly controversial.²⁹⁾³⁰⁾

Several explanations have been suggested for observed disagreement in research findings, such as in the case of MI. Studies using electronic health records often determine drinking status using proxy measures, and may lead to problems of misclassification.³¹⁾ This differs markedly from the case-control design of the Kaiser Permanente Health Plan Study for example, which used questionnaires to determine levels of alcohol consumption.¹⁰⁾²⁷⁾ The divergence in association estimates with respect to alcohol and CVD related illness could also be due to residual confounding, whereby alcohol appears protective due to its correlation with an unobserved factor protective for CVD risk.

In the Korean population, several studies have identified alcohol as a risk factor for CVD related illness. Yoon et al.³²⁾ find alcohol to be positively associated with metabolic syndrome, and subsequent onset of CVD. Regarding the protective effect of mild alcohol consumption, a systematic review and meta-analysis conducted by Park et al found no evidence of an inverse association between alcohol and CVD in the Korean population.³³⁾

Smoking

Smoking has been identified as a risk factor for CVD, with a positive relationship between the number of cigarettes smoked and CVD related illness.³⁴⁾³⁵⁾ The effects of tobacco smoke have been shown to extend to second-hand smoking, whilst smoking cessation has been shown to substantially reduce CVD risk.³⁴⁾³⁶⁾ Previous work stemming from the Korean Life Course Health Study and Korea Medical Insurance Corporation Study has identified smoking as a major independent risk factor for a range of CVD related illness, including ischaemic heart disease, CVD, and atherosclerotic CVD.³⁷⁾³⁸⁾ Further, the effects of smoking on atherosclerotic CVD has been found to be independent of low-cholesterol levels.³⁷⁾ Further studies have echoed these findings within East Asia and Korea, finding strong evidence of a connection between smoking behaviour and CVD risk.³⁹⁾⁴⁰⁾

Obesity and C-reactive protein

Increases in adiposity, and obesity specifically, have been argued to be an independent risk factor for CVD and all-cause mortality.⁴¹⁾ Using body mass index (BMI) as a measure of adiposity, it has been shown that higher levels of BMI increase risk of CVD related illness.⁴²⁾⁴³⁾ Obesity has been implicated in the development of atherosclerosis and MI.⁴⁴⁾⁴⁵⁾ Adiposity has also been shown to be positively associated with ischaemic and haemorrhagic stroke.⁴⁴⁾⁴⁵⁾ Higher levels of BMI during childhood have also been shown to increase CHD risk in later life.⁴⁶⁾⁴⁷⁾ The relationship between obesity and CVD has been found to hold in East Asian populations, and specifically in Korea.⁴⁸⁾ For example, Choi et al.⁴⁹⁾ find evidence of a positive

association between obesity and weight change with respect to CHD in Young Korean adults using data from the Korean National Health Insurance Service.

In recent years, much attention has been given to the role of C-reactive protein (CRP) in the development of CVD.⁴⁵⁾⁵⁰⁾ Whilst CRP has been identified as a biomarker for CVD related illness, it has not been clear whether CRP is causally relevant in the development of CVD, and consequently whether it would serve as an effective drug target.⁵⁰⁾⁵¹⁾ It has been suggested for example, that CRP could serve as a mediator in relation to LDL-C.⁵²⁾ Alternative assessments of the role of CRP emphasise that CRP may simply be correlated with true risk factors of CVD.⁵³⁾ As a consequence, while CRP is useful in predicting onset of CVD, the efficacy of interventions aimed at reducing CRP is unclear from observational studies alone.⁵¹⁾

Physical activity

There is growing evidence linking physical activity to CVD, and specifically CHD events.⁵⁴⁾ Sedentary individuals have been shown to have an increased risk of CVD related illness, though this could likely be driven by correlations between physical activity and alternative risk factors for CVD, such as obesity.⁵⁵⁾ However, whilst this relationship appears to hold regardless of gender, there is much debate over exercise guidelines and defining at-risk groups using arbitrary thresholds. An apparent dose-response relationship between physical activity and the reduction of CVD risk is suggested by previous research, but individuals at extreme levels of inactivity appear to be at a disproportionately high risk for CVD.⁵⁶⁾ These findings have been confirmed by several studies specific to Korea, though the extent to which physical activity is causally associated with CVD risk independent of risk factors such as obesity is uncertain.³⁹⁾ Using data from the South Korean health insurance system, Kim et al.⁵⁷⁾ find evidence of an inverse association between physical activity and CVD, independent of adiposity, smoking, and alcohol consumption.

Hypertension

Elevated blood pressure levels are widely accepted to be a risk factor for CVD events, based on findings from observational analyses.⁵⁸⁾⁵⁹⁾ However, while both systolic blood pressure (SBP) and diastolic blood pressure (DBP) seem to have a continuous, independent, and positive association with CVD, it is important to highlight the difficulties in using an arbitrary threshold to classify hypertension cases.⁶⁰⁾ It has been argued that regional and demographic differences in blood pressure levels should be taken into account, in particular with respect to age where young adults exhibiting multiple risk factors may fail to reach high risk levels, owing to the strength of age as a risk factor for CVD. In East Asian populations, hypertension has been shown to be positively associated with CVD risk.⁶¹⁾⁶²⁾ Lawes et al.⁶¹⁾ found evidence of an association between hypertension and CVD through a pooled meta-analysis of studies specific to the Asia-Pacific region. In Korea specifically, Son et al.⁶³⁾ observe a positive association using data from the Korean National Health Insurance system.

Type 2 diabetes

In observational analyses, diabetes and glucose intolerance have been shown to increase the risk of CVD related illness, especially in female populations.⁶⁴⁾⁶⁵⁾ It is important to note, however, that type 2 diabetes is associated with many risk factors of CVD related illness, including lipids, adiposity, and hypertension as previously discussed.⁶⁶⁾ As a consequence, it can be difficult to estimate the independent contribution of type 2 diabetes to CVD whilst controlling for potential confounding variables. Insulin resistance and metabolic syndrome have also been suggested as potential mechanisms for risk factors related to CVD, though

there is much debate surrounding definitions of metabolic syndrome and its efficacy as an aggregate measure relative to assessing individual risk factors.⁶⁾⁶⁷⁾ A number of studies, including the Asia Pacific Cohort Studies Collaboration (APCSC) meta-analysis project, show evidence of a strong positive association between diabetes mellitus and stroke in Asian populations, including Korea.⁶⁸⁻⁷⁰⁾

GENETICS AND METABOLOMICS OF CARDIOVASCULAR DISEASE

The emergence of large-scale genetic data has heralded a paradigm shift in epidemiology, allowing for genetic analyses contributing to our understanding of the aetiology of disease. Identifying genetic variants directly associated with a disease can illuminate potential drug targets, as well as highlight genetic predisposition to disease onset. Further, the existence of genetic variants simultaneously associated with both a disease outcome and previously identified risk factors can lend support to findings obtained from observational analyses.

In 2007, the first GWASs were published for CHD, identifying a locus on chromosome 9p21 to be robustly associated with CHD ($p=5\times 10^{-8}$).⁷¹⁻⁷³⁾ GWASs of CVD have since contributed to the identification of approximately 70 susceptibility loci, as shown in **Table 1**. A number of these loci can be linked to risk factors previously identified, for example, approximately 20% are located near genes with known roles in lipid metabolism and 5–10% are located near genes associated with blood pressure.

Table 1. Genetic variants from genome-wide association studies associated with CVD

Chr/SNP	Af	Gene	Risk factor	Study (year)
1/rs11206510	T (0.82)	<i>PCSK9</i>	LDL-C	Myocardial Infarction Genetics Consortium (2009),
1/rs17114036	A (0.91)	<i>PPAP2B</i>	-	Schunkert et al. (2011)
1/rs17465637	C (0.74)	<i>MIA3</i>	-	Schunkert et al. (2011)
1/rs599839	A (0.78)	<i>SORT1</i>	LDL-C	Schunkert et al. (2011)
1/rs4845625	T (0.47)	<i>IL6R</i>	IL-6	CARDIoGRAMplusC4D Consortium (2013)
1/rs6666258	C (0.29)	<i>KCNN3</i>	-	Ellinor et al. (2012)
1/rs3903239	G (0.44)	<i>PRRX1</i>	Height*	Ellinor et al. (2012)
2/rs6544713	T (0.30)	<i>ABCG5/ABCG8</i>	LDL-C	Schunkert et al. (2011),
2/rs6725887	C (0.15)	<i>WDR12</i>	Adiposity*	Schunkert et al. (2011),
2/rs515135	G (0.83)	<i>APOB</i>	Lipids*†	CARDIoGRAMplusC4D Consortium (2013)
2/rs2252641	G (0.46)	<i>ZEB2</i>	-	CARDIoGRAMplusC4D Consortium (2013)
2/rs1561198	A (0.45)	<i>VAMP5VAMP8-GGCX</i>	Adiposity*	CARDIoGRAMplusC4D Consortium (2013)
3/rs2306374	C (0.18)	<i>MRAS</i>	Adiposity*	Erdmann et al. (2009) and Schunkert et al. (2011)
3/rs4642101	G (0.65)	<i>CAND2</i>	-	Sinner, et al. (2014)
4/rs7692387	G (0.81)	<i>GUCY1A3</i>	Hypertension	CARDIoGRAMplusC4D Consortium (2013)
4/rs1878406	T (0.15)	<i>EDNRA</i>	-	CARDIoGRAMplusC4D Consortium (2013)
4/rs17087335	T (0.21)	<i>REST-NOA1</i>	Height/Adiposity*	Nikpay et al. (2015)
4/rs6817105	C (0.13)	<i>PITX2</i>	-	Ellinor et al. (2012)
5/rs2706399	G (0.51)	<i>IL5</i>	-	IBC 50K CAD Consortium (2011)
5/rs273909	C (0.14)	<i>SLC22A4-A5</i>	Height/Adiposity	CARDIoGRAMplusC4D Consortium (2013)
6/rs12526453	C (0.67)	<i>PHACTR1</i>	-	Schunkert et al. (2011)
6/rs17609940	G (0.75)	<i>ANKS1A</i>	Adiposity/Height*	Schunkert et al. (2011)
6/rs12190287	C (0.62)	<i>TCF21</i>	-	Schunkert et al. (2011)
6/rs3798220	C (0.02)	<i>LPA, SLC22A3, LPAL2</i>	LP(a)/LDL-C	Schunkert et al. (2011)
6/rs10947789	T (0.76)	<i>KCNK5</i>	Height*	CARDIoGRAMplusC4D Consortium (2013)
6/rs4252120	T (0.73)	<i>PLG</i>	LP(a)	CARDIoGRAMplusC4D Consortium (2013)
6/rs13216675	T (0.69)	<i>GJA1</i>	-	Sinner, et al. (2014)
7/rs10953541	C (0.80)	<i>BCAP29</i>	-	Coronary Artery Disease C4D Genetics Consortium (2011)

(continued to the next page)

Table 1. (Continued) Genetic variants from genome-wide association studies associated with CVD

Chr/SNP	Af	Gene	Risk factor	Study (year)
7/rs11556924	C (0.62)	ZC3HC1	Hypertension/Height	Schunkert et al. (2014)
7/rs2023938	G (0.10)	HDAC9	Hypertension/Height*	CARDIoGRAMplusC4D Consortium (2013)
7/rs3918226	T (0.06)	NOS3	Adiposity/Height/Hypertension	Nikpay et al. (2015)
7/rs3807989	A (0.40)	CAV1	-	Ellinor et al. (2012)
8/rs2954029	A (0.55)	TRIB1	Lipids [†]	CARDIoGRAMplusC4D Consortium (2013)
8/rs264	G (0.86)	LPL	Lipids [†]	Stitzel et al. (2016)
9/rs4977574	G (0.46)	9p21.3	-	Schunkert et al. (2011)
9/rs579459	C (0.21)	ABO	LDL-C	Schunkert et al. (2011)
9/rs111245230	C (0.04)	SVEP1	Hypertension	Stitzel et al. (2016)
9/rs10821415	A (0.42)	C9orf3	Height/Adiposity	Ellinor et al. (2012)
10/rs2505083	C (0.38)	KIAA1462	-	Coronary Artery Disease C4D Genetics Consortium (2011)
10/rs1746048	C (0.87)	CXCL12	-	Schunkert et al. (2011)
10/rs1412444	T (0.42)	LIPA	-	Coronary Artery Disease C4D Genetics Consortium (2011)
10/rs12413409	G (0.89)	CYP17A1, NT5C2	Hypertension/Adiposity	Schunkert et al. (2011)
10/rs10824026	G (0.15)	SYNPO2L	Hypertension	Ellinor et al. (2012)
11/rs974819	T (0.32)	PDGFD	-	Coronary Artery Disease C4D Genetics Consortium (2011)
11/rs964184	G (0.13)	APOA1-C3-A4-A5	Lipids [†]	Do et al. (2015, 2013)
12/rs10840293	A (0.55)	SWAP70	Hypertension	Nikpay et al. (2015)
12/rs3184504	T (0.44)	SH2B3, HNF1A	Lipids [†] /Adiposity/T1D/Hypertension	Schunkert et al. (2011)
12/rs11830157	G (0.36)	KSR2	-	Nikpay et al. (2015)
12/rs10507248	T (0.73)	TBX5	-	Sinner, et al. (2014)
13/rs4773144	G (0.44)	COL4A1, COL4A2	Hypertension	Schunkert et al. (2011)
13/rs9319428	A (0.32)	FLT1	-	CARDIoGRAMplusC4D Consortium (2013)
14/rs2895811	C (0.43)	HHIPL1	-	Schunkert et al. (2011)
14/rs1152591	A (0.47)	SYNE2	Height	Ellinor et al. (2012)
15/rs3825807	A (0.57)	ADAMTS7	Smoking	Schunkert et al. (2011)
15/rs17514846	A (0.44)	FURIN-FES	Hypertension	CARDIoGRAMplusC4D Consortium (2013)
15/rs56062135	C (0.79)	SMAD3	Adiposity	Nikpay et al. (2015)
15/rs8042271	G (0.9)	MFG8-ABHD2	Height	Nikpay et al. (2015)
15/rs7164883	G (0.16)	HCN4	Adiposity*	Ellinor et al. (2012)
16/rs2106261	T (0.17)	ZFH3	-	Ellinor et al. (2012)
17/rs216172	C (0.37)	SMG6-SRR	Adiposity	Schunkert et al. (2011)
17/rs12936587	G (0.56)	PEMT, RASD1, SMCR3	-	Schunkert et al. (2011)
17/rs46522	T (0.53)	UBE2Z, GIP	Height/Adiposity	Schunkert et al. (2011)
17/rs7212798	C (0.15)	BCAS3	-	Nikpay et al. (2015)
18/rs663129	A (0.26)	PMAIP1-MC4R	Adiposity/Lipids* [†]	Nikpay et al. (2015)
19/rs116843064	G (0.98)	ANGTPL4	Lipids [†]	Stitzel et al. (2016)
19/rs1122608	G (0.77)	LDLR	LDL-C	Do et al. (2015)
19/rs2075650	G (0.14)	APOE	Lipids [†] /CRP/Adiposity	IBC 50K CAD Consortium (2011),
19/rs12976411	A (0.91)	ZNF507-LOC400684	-	Nikpay et al. (2015)
21/rs9982601	T (0.15)	MRPS6, SLC5A3, KCNE2	Hypertension	Myocardial Infarction Genetics Consortium (2009)
22/rs180803	G (0.97)	POM121L9P-ADORA2A	-	Nikpay et al. (2015)

Af = allele frequencies; CAD = coronary artery disease; Chr = chromosome; CRP = C-reactive protein; CVD = cardiovascular disease; HDL-C = high-density lipoprotein cholesterol; IL = interleukin; LDL-C = low-density lipoprotein cholesterol; SNP = single-nucleotide polymorphism.

*Risk factor is not directly associated with lead SNP but is associated with one or more SNPs within gene region; [†]SNP is associated with 2 or more different lipid fractions (LDL-C, HDL-C, and triglycerides).

The discovery of genetic variants simultaneously associated with CVD outcomes and LDL-C provides evidence of a potential role of LDL-C in CVD development. However, it should be noted that several studies report variants associated with LDL-C, HDL-C, and triglycerides simultaneously (denoted lipids in **Table 1**). In these cases, it is not possible to clearly distinguish which lipid fraction is potentially driving the association between the variant and CVD. Hypertension and adiposity are also linked with several of the genetic variants, further supporting evidence from observational analyses. In **Table 1**, we include height as a risk factor as it is a component of BMI.

It is important to emphasise, however, that the extent to which genetic analyses can support observational studies is dependent upon heritability of a given risk factor. Adiposity and height are, for example, highly heritable traits as opposed to behavioural risk factors such as smoking. As such, the absence of genetic studies supporting observational analyses does not necessarily invalidate observational findings. This could for example explain the lack of genetic variants associated with CVD and physical activity. In related work using data from KCPS-II Biobank, Jung et al utilise a genetic risk score to predict CVD incidence, comparing the accuracy to a score using traditional risk factors.²⁵⁾ They found that combining information using both scores substantially improved predictive accuracy, suggesting there may likely be a strong genetic component to CVD in the Korean population.

Technological advances in measuring metabolites have facilitated analyses focusing specifically upon role of metabolites in disease onset and progression. As an emergent field, metabolomics focuses upon molecular changes which occur in different disease states, elucidating the underlying biological mechanisms behind disease and allowing for effective biomarkers to be identified.⁷⁴⁻⁷⁶⁾ As disturbances in cardio-metabolic processes often accompany CVD, it has been possible for metabolite profiling to be applied to CVD in order to evaluate the potential role of metabolites.⁷⁴⁾⁷⁵⁾

Such studies have provided evidence linking a range of metabolites present in plasma levels with CVD. For example, metabolomic studies of heart failure using mouse models have highlighted the coordinated downregulation of branch chain amino acids (BCAAs) in failing hearts.⁷⁵⁾⁷⁷⁾ Whilst these findings have been replicated in humans, metabolomic studies typically rely upon serum metabolite measures, which may suffer from issues related specificity.⁷⁸⁾ However, despite these limitations a number of potential biomarkers for CVD have been identified. These include phosphatidylserine, C16-sphingosine, N-methyl arachidonic amide, N-(2-methoxyethyl) arachidonic amide, linoleamidoglycerophosphate choline, lysoPC (C18:2), lyso-PC (C16:0), lyso-PC (C18:1), arachidonic acid, and linoleic acid.⁷⁹⁻⁸²⁾

MENDELIAN RANDOMIZATION AND CARDIOVASCULAR DISEASE

Mendelian randomization: overview

MR is a causal inference approach which corrects for bias resulting from residual confounding.⁸³⁾ Such bias occurs when variables serving as joint determinants of the exposure and outcome of interest are omitted from analyses, resulting in associations between the omitted variables and the outcome being erroneously attributed to the exposure. MR corrects for residual confounding by employing genetic variants as instrumental variables (IVs).⁸³⁾ In their seminal work, Smith and Ebrahim⁸³⁾ demonstrate how genetic variants can serve as IVs and illustrate how the same principles can be applied within medical research. This has led to the rapid development of formal statistical approaches, which allow for causal relationships to be identified.⁸⁴⁻⁹⁰⁾

Conventional MR analyses rely upon three central assumptions for unbiased effect estimation. Firstly, genetic instruments must be strongly associated with the exposure of interest (IV1).⁹¹⁾ Candidate instruments are typically identified using GWAS, with the extent to which an IV explains variation in an exposure of interest referred to as instrument strength. Second, genetic instruments are required to be independent of unmeasured confounders of




Figure 1. A directed acyclic graph illustrating the Mendelian randomization assumptions. *G* represents a genetic instrument, *X* and *Y* are the exposure and outcome of interest respectively, and *U* denotes one or more unmeasured confounders of the exposure and outcome. In the diagram, the bold arrow from *G* to *X* indicates the association between the instrument and exposure necessary to satisfy assumption IV1. The dashed arrows indicate associations which would, if non-zero, invalidate the second and third MR assumptions (IV2–3).

the exposure and outcome (IV2).⁹¹⁾ The use of genetic variants as instruments is particularly useful in this case, as the random assortment of alleles at conception restricts the range of possible associations which can occur. Third, genetic instruments must be independent of the study outcome when conditioning on the exposure of interest (IV3).⁹²⁾⁹³⁾ Associations which violate assumption IV3 are referred to as horizontal pleiotropic pathways, inducing bias in the direction of pleiotropic association.⁹³⁾ The assumptions of MR are illustrated in **Figure 1**.

Mendelian randomization: current methods

Initially, MR was conceived at a point where a relative paucity of genetic data was available, owing to the scarcity and expense of GWASs. Consequently, early MR studies typically featured small sample sizes, selected genetic instruments informed by candidate gene studies, and utilised individual level data. However, the recent proliferation of GWASs and emergence of large-scale biobank projects such as the China-Kadoorie Biobank have served to motivate the wide-spread application of MR, including methods leveraging publicly available GWAS summary data.⁸⁴⁾⁸⁵⁾⁹⁴⁾ The availability of GWAS summary data with increasingly large sample sizes is advantageous in allowing for candidate instruments to be identified using separate non-overlapping samples. This improves the power to detect suitable instruments, as well as limiting bias due to winner's curse; occurring when a genetic variant is observed to be associated with a phenotype of interest purely by chance.

The increase in publicly available GWAS summary data has also motivated the development of myriad MR approaches which are able to furnish MR estimates without requiring access to individual level data. These methods utilise association estimates and standard errors for each genetic instrument with the exposure and outcome using separate samples, calculating a Wald ratio estimate for each genetic instrument.⁸⁴⁾⁹⁴⁾ The Wald ratio, calculated by dividing the instrument-outcome association by the instrument-exposure association, serves as an MR causal effect estimate using a single genetic instrument. Summary level MR methods then typically evaluate the set of Wald ratios within a meta-analytic framework, through methods such as inverse-variance weighted (IVW) and MR-Egger regression.⁸⁴⁾⁹⁴⁾

The emergence of large-scale biobanks has also prompted the development of a range of individual level data approaches to MR. This allows researchers to incorporate more information into estimates of causal effect, such as allowing the inclusion of additional variables for adjustment and incorporating gene-by-environment interactions and non-linear models.⁹⁵⁾⁹⁶⁾

Mendelian randomization applications to cardiovascular disease

To assess the contributions of MR to studies focusing on cardiovascular health, we conducted a systematic review using PubMed and Web of Science. Using a comprehensive search strategy




Figure 2. A flow chart showing the selection process for relevant papers.

(see web appendix), we identified MR studies where CVD, coronary artery disease (CAD), CHD, heart disease, MI, or stroke served as an outcome during the period 2003–2019. All identified publications underwent a 3-step review of title, abstract, and full text based on predefined inclusion criteria. We excluded meta-analyses, review papers and studies incorporating interventions, as well as animal and laboratory studies. For each eligible study, we extracted the lead author's name, journal name, publication year, and study population. We identify a total of 126 eligible MR studies, conducted from 2003–2019, as shown in **Figure 2**.

Lipids

Several MR analyses have focused on the role of serum lipids, and specifically LDL-C, in the development of CVD. LDL-C has consistently been shown to be positively associated with CAD, CHD, ischemic stroke, and MI in MR analyses.⁹⁷⁻¹⁰¹ Triglycerides have also been shown to be positively associated with CAD, CHD, and MI.^{97,102} It is interesting to note, however, that the observed inverse association between HDL-C and CVD has not been shown to hold in MR studies particularly in relation to CHD and MI.¹⁰²⁻¹⁰⁴

As previously discussed, a concern when assessing the role of lipid fractions is the correlation between LDL-C, HDL-C, and triglycerides. In the context of MR, using such variants as an instrument for a single lipid fraction would likely result in bias in cases where additional lipid fractions are independently causal with respect to CVD, as this would violate the third MR assumption (IV3). Studies using variants specific to HDL-C have not found evidence of an association with CVD related illness, though this could potentially be due to a lack of enough statistical power.¹⁰³

A potential solution to this problem is the application of multivariable MR methods, which allow for multiple risk factors to be adjusted for provided they independently explain sufficient variation in each exposure.⁹⁰ Several studies have implemented this research design, finding evidence of a positive association between LDL-C and CVD outcomes, whilst HDL-C does not appear to have a substantial effect.^{105,106}

Alcohol consumption

MR studies have also supported the observed link between alcohol consumption and CVD outcomes. Findings from the China-Kadoorie Biobank, comprised predominantly of Chinese

participants, have shown a positive association between alcohol and subtypes of stroke using both MR and observational approaches.³⁰⁾ This observed association between stroke outcomes and alcohol consumption has also been replicated in European populations.¹⁰⁷⁾

Alcohol consumption has also been linked to wider CVD outcomes in a number of MR studies including Korea specific populations.³⁰⁾¹⁰⁸⁾¹⁰⁹⁾ For example, several studies have utilised gene-by-environment MR approaches to examine the association between alcohol and CVD in East Asian populations, leveraging gender-specific differences in drinking behaviour.¹⁰⁸⁾¹¹⁰⁾ In an analysis using data from the Korean Genome and Epidemiology Study (KoGES), Cho et al.¹⁰⁸⁾ find evidence of an association between alcohol consumption and cardiovascular health. Findings from Jee et al.¹¹¹⁾ using data from KCPS-II Biobank also find evidence of an association between alcohol and hyperuricemia in males using data from KCPS-II Biobank.

Obesity and C-reactive protein

The relationship between adiposity, often measured using BMI, and CVD has also received substantial attention in the MR literature. CAD, for example, has been found to be positively associated with adiposity in a number of studies.¹¹²⁻¹¹⁶⁾ Importantly, differing measures of adiposity have often been included such as waist-to-hip ratio, so as to limit the extent to which the findings are an artefact of selecting BMI as the primary measure of adiposity.¹¹³⁾¹¹⁷⁾ Adiposity has also been found to be a risk factor for many CVD related diseases, including stroke and CHD.¹¹⁸⁻¹²⁰⁾ In MR analyses focusing upon the role of CRP in the development of CVD related illness, there appears to be no substantial evidence of causal association.¹²¹⁻¹²⁴⁾ Such findings provide support for the use of CRP as a biomarker, rather than a target for intervention.

Type 2 diabetes

Whilst many MR studies focus upon diabetes as an outcome rather than a risk factor, several studies suggest diabetes and glucose are risk factors for CVD related illness. Altered glucose levels have been found to be associated with CAD independent of adiposity and are thought to be a mechanism through which diabetes causes CAD.¹¹²⁾¹²⁵⁾ Diabetes has also been estimated to be positively associated with CHD and large artery stroke.¹²⁶⁾¹²⁷⁾

Finally, it is important to emphasise that where a binary exposure is evaluated within a summary MR framework a subtle difference in interpretation is required. Essentially, the effect estimate is not the effect of the disease itself, but rather the phenotypic effects of general liability to that disease.¹²⁸⁾

Smoking, physical activity, and hypertension

At this point there is a relative gap in the MR literature pertaining to smoking, physical activity, and hypertension as risk factor for CVD. Studies conducted in European populations have found evidence of a positive association between SBP and CVD events, confirming findings from observational analyses.¹²⁹⁾ In a Norwegian population, smoking has been found to be a risk factor for several potential downstream risk factors of CVD, though a direct association between CVD and smoking was not examined.¹³⁰⁾ Unfortunately, there appears to be insufficient evidence from MR related studies to explore the role of physical activity in CVD.¹³¹⁾ As with genetic analyses, MR studies are reliant upon risk factors being highly heritable, which translates to instrument strength. In the case of behavioural risk factors, it is often not possible to identify genetic variants which can explain a enough proportion of the variance of a given risk factor to provide a sufficiently precise estimate of causal effect.

PRECISION MEDICINE AND FUTURE DIRECTIONS

By assessing findings of CVD analyses using a range of study designs, it is possible to identify several relationships which are consistently present. The relationship between LDL-C and CVD remains strong across observational, genetic, and MR analyses, and across populations of differing ethnic background. However, similar agreement across studies assessing the protective effects of HDL-C is not present. There are 2 likely explanations for why this is the case. In the first instance, the observed association between HDL-C could be due to residual confounding, such that one or more risk factors are highly correlated with HDL-C but omitted from the analyses. However, as it is common practice to control for LDL-C when estimating the effects of HDL-C, identification of the omitted risk factors remains unclear. A second possibility is that the assumptions of the MR approach may be violated, leading to biased estimates. This could be the case where, for example, genetic instruments are simultaneously correlated with both HDL-C and LDL-C.

The example of LDL-C illustrates the potential to detect effective drug targets, such as the use of statins in lowering CVD related illness. Statins are medicines which specifically aim to lower serum LDL-C and have been shown to effectively reduce risks of CVD related illness. In the previous analyses, evidence for a relationship between LDL-C was found using observational, genetic, and MR methods, and the agreement across these studies of differing design highlight the therapeutic effectiveness of statins in retrospect.

A further related drug target demonstrated by genetic studies is the development of monoclonal antibodies against *PCSK9*.¹³²⁾ *PCSK9* is a liver protease that targets low-density lipoprotein receptors for lysosomal degradation. Subsequent MR analyses have confirmed genetic findings, highlighting the therapeutic potential of targeting *PCSK9*.¹³³⁾ These findings have led to recommendations for low-density lipoprotein lowering with *PCSK9* inhibitors to be provided for high-risk patients with LDL-C levels ≥ 70 mg/dL on maximally tolerated oral therapies.¹³⁴⁾ Two additional targets, *CYP2C9* and *VKORCI*, have also been identified in GWASs, showing an association with inter-individual variability in warfarin dose.¹³⁵⁾¹³⁶⁾ This suggests that genes in the warfarin metabolism pathway are associated with dose variance.¹³⁵⁾¹³⁶⁾ Though these studies were performed in Japanese populations, additional studies confirmed these variants for personalized warfarin treatment in different ethnic groups.¹³⁷⁾

Recent research has highlighted the potential for Lp(a) as a potential drug target for lowering CHD risk.¹³⁸⁾ MR analyses focusing on Lp(a) find evidence suggesting that pharmacologically lowering Lp(a) concentration by approximately 100 mg/dL can potentially reduce CHD risk by as much as 25%.¹³⁸⁾ However, the efficacy of Lp(a) as a drug target is somewhat controversial, with randomized controlled trials (RCTs) finding no substantial benefit using treatments specifically targeting Lp(a) with respect to cardiovascular events.¹³⁹⁻¹⁴¹⁾ The disagreement in findings between MR and RCT studies is explained in part by the limited suitability of Lp(a) targeting drugs to individuals with high concentrations of Lp(a). As such treatments are best suited to individuals with very high levels of Lp(a), with diminishing returns as Lp(a) concentration declines.¹³⁸⁾ This is encapsulated by the risk of CHD being estimated to be linearly proportional to the absolute difference in Lp(a) concentration across study samples.¹³⁸⁾

Like the example of LDL-C, obesity and adiposity have been shown to be consistently associated with CVD across varying types of study. Increased BMI has been estimated to be

positively associated with CVD independent of LDL-C, which is conventionally controlled for in observational analyses. Simultaneous associations between adiposity and CVD outcomes, as illustrated in **Table 1**, also support the existence of a causal association in conjunction with findings from MR analyses. However, it is important to highlight that substantial divergence in study findings with respect to CRP suggest drugs targeting CRP specifically will be unlikely to be effective.

The protective effects of low doses of alcohol with respect to CVD are not found to be consistent across different study designs. MR analyses performed using alcohol consumption as an exposure find evidence of a positive association between alcohol and CVD, although there are currently only a relatively small number of relevant studies. It seems possible that consumption of only small amounts of alcohol is negatively correlated with alternative risk factors, for example adiposity or type-II diabetes, which are driving the observed protective effect of alcohol through confounding bias. Further studies evaluating the causal impact of alcohol consumption would prove invaluable in elucidating the potential pathways between alcohol consumption and CVD.

There are, however, gaps in the MR literature which warrant further examination. For example, smoking, physical activity, and hypertension have all been previously identified to be risk factors for CVD related illness. However, conducting a systematic review of MR studies highlights a notable gap in the literature with respect to these risk factors. Several studies have considered these risk factors as part of wider studies related to cardiovascular health, in particular work by Burgess et al.¹³⁸⁾ and Carter et al.¹⁴²⁾ However, more work focusing on replicating MR findings is required.

Considering smoking, one potential issue is the limited number of genetic variants associated with smoking behaviour. In MR analyses, and particularly 2-sample summary analyses, the relative weakness of genetic variants as instruments for smoking behaviour results in a lack of sufficient precision to detect causal associations. However, this issue can be effectively addressed with the growing sample sizes of studies with genetic data, and the subsequent increases in precision afforded to researchers.

CONCLUSIONS

In this review we have critically examined research identifying risk factors for CVD using observational, genetic, and MR study designs. By assessing findings across multiple study designs, each with independent sources of bias, it is possible to identify consistent relationships which appear to be robust to the limitations of each research methods. This strengthens the extent to which such findings can be robust and serve as potential targets for precision medicine. We identify LDL-C, alcohol, and obesity as notable risk factors, as well as several candidate risks which warrant further attention.

REFERENCES

1. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. *Circulation* 2019;139:e56-528.

[PUBMED](#) | [CROSSREF](#)

2. Organisation for Economic Cooperation and Development (OECD). *Cardiovascular Disease and Diabetes: Policies for Better Health and Quality of Care*. Paris: OECD Publishing; 2015.
[CROSSREF](#)
3. Lawlor DA, Tilling K, Davey Smith G. Triangulation in aetiological epidemiology. *Int J Epidemiol* 2016;45:1866-86.
[PUBMED](#) | [CROSSREF](#)
4. Buttar HS, Li T, Ravi N. Prevention of cardiovascular diseases: Role of exercise, dietary interventions, obesity and smoking cessation. *Exp Clin Cardiol* 2005;10:229-49.
[PUBMED](#)
5. Jee YH, Emberson J, Jung KJ, et al. Cohort profile: the Korean Cancer Prevention Study-II (KCPS-II) Biobank. *Int J Epidemiol* 2018;47:385-386f.
[PUBMED](#) | [CROSSREF](#)
6. O'Donnell CJ, Elosua R. Cardiovascular risk factors. Insights from Framingham Heart Study. *Rev Esp Cardiol* 2008;61:299-310.
[PUBMED](#) | [CROSSREF](#)
7. Denaxas SC, George J, Herrett E, et al. Data resource profile: cardiovascular disease research using linked bespoke studies and electronic health records (CALIBER). *Int J Epidemiol* 2012;41:1625-38.
[PUBMED](#) | [CROSSREF](#)
8. Bell S, Daskalopoulou M, Rapsomaniki E, et al. Association between clinically recorded alcohol consumption and initial presentation of 12 cardiovascular diseases: population based cohort study using linked health records. *BMJ* 2017;356:j909.
[PUBMED](#) | [CROSSREF](#)
9. Klatsky AL, Armstrong MA, Friedman GD, Sidney S. Alcohol drinking and risk of hospitalization for ischemic stroke. *Am J Cardiol* 2001;88:703-6.
[PUBMED](#) | [CROSSREF](#)
10. Klatsky AL, Friedman GD, Siegel AB. Alcohol use and cardiovascular disease: the Kaiser-Permanente experience. *Circulation* 1981;64:III 32-41.
[PUBMED](#)
11. The Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. The pooling project research group. *J Chronic Dis* 1978;31:201-306.
[PUBMED](#) | [CROSSREF](#)
12. Ference BA, Graham I, Tokgozoglul L, Catapano AL. Impact of lipids on cardiovascular health: JACC Health Promotion Series. *J Am Coll Cardiol* 2018;72:1141-56.
[PUBMED](#) | [CROSSREF](#)
13. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004;364:937-52.
[PUBMED](#) | [CROSSREF](#)
14. Robertson TL, Kato H, Rhoads GG, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. Incidence of myocardial infarction and death from coronary heart disease. *Am J Cardiol* 1977;39:239-43.
[PUBMED](#) | [CROSSREF](#)
15. National Heart Lung and Blood Institute. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. *JAMA* 1984;251:365-74.
[PUBMED](#) | [CROSSREF](#)
16. Anderson TW, Rubin H. Estimation of the parameters of a single equation in a complete system of stochastic equations. *Ann Math Stat* 1949;20:46-63.
[CROSSREF](#)
17. Gofman JW, Young W, Tandy R. Ischemic heart disease, atherosclerosis, and longevity. *Circulation* 1966;34:679-97.
[PUBMED](#) | [CROSSREF](#)
18. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. *Ann Intern Med* 1979;90:85-91.
[PUBMED](#) | [CROSSREF](#)
19. Salonen JT, Salonen R, Seppänen K, Rauramaa R, Tuomilehto J. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. *Circulation* 1991;84:129-39.
[PUBMED](#) | [CROSSREF](#)

20. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. *Am J Cardiol* 2002;90:89-94.
[PUBMED](#) | [CROSSREF](#)
21. Kosmas CE, Martinez I, Sourlas A, et al. High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease. *Drugs Context* 2018;7:212525.
[PUBMED](#) | [CROSSREF](#)
22. Castelli WP, Doyle JT, Gordon T, et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. *Circulation* 1977;55:767-72.
[PUBMED](#) | [CROSSREF](#)
23. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation* 2011;123:2292-333.
[PUBMED](#) | [CROSSREF](#)
24. Jeong SM, Choi S, Kim K, et al. Effect of change in total cholesterol levels on cardiovascular disease among young adults. *J Am Heart Assoc* 2018;7:e008819.
[PUBMED](#) | [CROSSREF](#)
25. Jung KJ, Hwang S, Lee S, Kim HC, Jee SH. Traditional and genetic risk score and stroke risk prediction in Korea. *Korean Circ J* 2018;48:731-40.
[PUBMED](#) | [CROSSREF](#)
26. Jee SH, Jang Y, Oh DJ, et al. A coronary heart disease prediction model: the Korean Heart Study. *BMJ Open* 2014;4:e005025.
[PUBMED](#) | [CROSSREF](#)
27. Klatsky AL, Friedman GD, Siegelaub AB. Alcohol consumption before myocardial infarction. Results from the Kaiser-Permanente epidemiologic study of myocardial infarction. *Ann Intern Med* 1974;81:294-301.
[PUBMED](#) | [CROSSREF](#)
28. Mukamal K, Lazo M. Alcohol and cardiovascular disease. *BMJ* 2017;356:j1340.
[PUBMED](#) | [CROSSREF](#)
29. Fernández-Solà J. Cardiovascular risks and benefits of moderate and heavy alcohol consumption. *Nat Rev Cardiol* 2015;12:576-87.
[PUBMED](#) | [CROSSREF](#)
30. Millwood IY, Walters RG, Mei XW, et al. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. *Lancet* 2019;393:1831-42.
[PUBMED](#) | [CROSSREF](#)
31. Mukamal K. Alcohol intake and noncoronary cardiovascular diseases. *Ann Epidemiol* 2007;17:S8-12.
[PUBMED](#) | [CROSSREF](#)
32. Yoon YS, Oh SW, Baik HW, Park HS, Kim WY. Alcohol consumption and the metabolic syndrome in Korean adults: the 1998 Korean National Health and Nutrition Examination Survey. *Am J Clin Nutr* 2004;80:217-24.
[PUBMED](#) | [CROSSREF](#)
33. Park JE, Choi TY, Ryu Y, Cho SI. The relationship between mild alcohol consumption and mortality in Koreans: a systematic review and meta-analysis. *BMC Public Health* 2015;15:918.
[PUBMED](#) | [CROSSREF](#)
34. Doyle JT, Dawber TR, Kannel WB, Heslin AS, Kahn HA. Cigarette smoking and coronary heart disease. Combined experience of the Albany and Framingham studies. *N Engl J Med* 1962;266:796-801.
[PUBMED](#) | [CROSSREF](#)
35. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. *N Engl J Med* 1990;322:213-7.
[PUBMED](#) | [CROSSREF](#)
36. National Center for Chronic Disease Prevention and Health Promotion (US). *How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General*. Atlanta (GA): Centers for Disease Control and Prevention; 2010.
37. Jee SH, Suh I, Kim IS, Appel LJ. Smoking and atherosclerotic cardiovascular disease in men with low levels of serum cholesterol: the Korea Medical Insurance Corporation Study. *JAMA* 1999;282:2149-55.
[PUBMED](#) | [CROSSREF](#)
38. Jee Y, Jung KJ, Lee S, Back JH, Jee SH, Cho SI. Smoking and atherosclerotic cardiovascular disease risk in young men: the Korean Life Course Health Study. *BMJ Open* 2019;9:e024453.
[PUBMED](#) | [CROSSREF](#)
39. Park K, Lim S, Park Y, Ju W, Shin Y, Yeom H. Cardiovascular disease risk factors and obesity levels in Korean adults: results from the Korea National Health and Nutrition Examination Survey, 2007–2015. *Osong Public Health Res Perspect* 2018;9:150-9.
[PUBMED](#) | [CROSSREF](#)

40. Cho MH, Lee K, Park SM, et al. Effects of smoking habit change on all-cause mortality and cardiovascular diseases among patients with newly diagnosed diabetes in Korea. *Sci Rep* 2018;8:5316.
[PUBMED](#) | [CROSSREF](#)
41. Engeland A, Bjørge T, Sjøgaard AJ, Tverdal A. Body mass index in adolescence in relation to total mortality: 32-year follow-up of 227,000 Norwegian boys and girls. *Am J Epidemiol* 2003;157:517-23.
[PUBMED](#) | [CROSSREF](#)
42. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. *Circulation* 2006;113:898-918.
[PUBMED](#) | [CROSSREF](#)
43. Kachur S, Lavie CJ, de Schutter A, Milani RV, Ventura HO. Obesity and cardiovascular diseases. *Minerva Med* 2017;108:212-28.
[PUBMED](#)
44. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. *Nat Rev Cardiol* 2009;6:399-409.
[PUBMED](#) | [CROSSREF](#)
45. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. *J Am Coll Cardiol* 2007;49:2129-38.
[PUBMED](#) | [CROSSREF](#)
46. Baker JL, Olsen LW, Sørensen TI. Childhood body-mass index and the risk of coronary heart disease in adulthood. *N Engl J Med* 2007;357:2329-37.
[PUBMED](#) | [CROSSREF](#)
47. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. *J Am Coll Cardiol* 2009;53:1925-32.
[PUBMED](#) | [CROSSREF](#)
48. Jee SH, Sull JW, Park J, et al. Body-mass index and mortality in Korean men and women. *N Engl J Med* 2006;355:779-87.
[PUBMED](#) | [CROSSREF](#)
49. Choi S, Kim K, Kim SM, et al. Association of obesity or weight change with coronary heart disease among young adults in South Korea. *JAMA Intern Med* 2018;178:1060-8.
[PUBMED](#) | [CROSSREF](#)
50. Cozlea DL, Farcas DM, Nagy A, et al. The impact of C reactive protein on global cardiovascular risk on patients with coronary artery disease. *Curr Health Sci J* 2013;39:225-31.
[PUBMED](#)
51. de Ferranti S, Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. *Clin Chim Acta* 2002;317:1-15.
[PUBMED](#) | [CROSSREF](#)
52. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. *Circulation* 2001;103:1194-7.
[PUBMED](#) | [CROSSREF](#)
53. Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. *Eur Heart J* 2000;21:1584-90.
[PUBMED](#) | [CROSSREF](#)
54. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. *Am J Epidemiol* 1990;132:612-28.
[PUBMED](#) | [CROSSREF](#)
55. Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. *Circulation* 2007;116:2110-8.
[PUBMED](#) | [CROSSREF](#)
56. Carnethon MR. Physical activity and cardiovascular disease: how much is enough? *Am J Lifestyle Med* 2009;3:44S-49S.
[PUBMED](#) | [CROSSREF](#)
57. Kim Y, Sharp S, Hwang S, Jee SH. Exercise and incidence of myocardial infarction, stroke, hypertension, type 2 diabetes and site-specific cancers: prospective cohort study of 257 854 adults in South Korea. *BMJ Open* 2019;9:e025590.
[PUBMED](#) | [CROSSREF](#)
58. Kannel WB, Sorlie P, Gordon T. Labile hypertension: a faulty concept? The Framingham study. *Circulation* 1980;61:1183-7.
[PUBMED](#) | [CROSSREF](#)

59. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002;360:1903-13.
[PUBMED](#) | [CROSSREF](#)
60. Kjeldsen SE. Hypertension and cardiovascular risk: general aspects. *Pharmacol Res* 2018;129:95-9.
[PUBMED](#) | [CROSSREF](#)
61. Lawes CM, Bennett DA, Parag V, et al. Blood pressure indices and cardiovascular disease in the Asia Pacific region: a pooled analysis. *Hypertension* 2003;42:69-75.
[PUBMED](#) | [CROSSREF](#)
62. Kim SJ, Lee J, Jee SH, et al. Cardiovascular risk factors for incident hypertension in the prehypertensive population. *Epidemiol Health* 2010;32:e2010003.
[PUBMED](#) | [CROSSREF](#)
63. Son JS, Choi S, Kim K, et al. Association of blood pressure classification in Korean young adults according to the 2017 American College of Cardiology/American Heart Association Guidelines With Subsequent Cardiovascular Disease Events. *JAMA* 2018;320:1783-92.
[PUBMED](#) | [CROSSREF](#)
64. Fox CS, Coady S, Sorlie PD, et al. Trends in cardiovascular complications of diabetes. *JAMA* 2004;292:2495-9.
[PUBMED](#) | [CROSSREF](#)
65. Goldschmid MG, Barrett-Connor E, Edelstein SL, Wingard DL, Cohn BA, Herman WH. Dyslipidemia and ischemic heart disease mortality among men and women with diabetes. *Circulation* 1994;89:991-7.
[PUBMED](#) | [CROSSREF](#)
66. Wilson PW, McGee DL, Kannel WB. Obesity, very low density lipoproteins, and glucose intolerance over fourteen years: the Framingham Study. *Am J Epidemiol* 1981;114:697-704.
[PUBMED](#) | [CROSSREF](#)
67. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2005;28:2289-304.
[PUBMED](#) | [CROSSREF](#)
68. Ueshima H. Explanation for the Japanese paradox: prevention of increase in coronary heart disease and reduction in stroke. *J Atheroscler Thromb* 2007;14:278-86.
[PUBMED](#) | [CROSSREF](#)
69. NIPPON DATA80 Research Group. Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. *Circ J* 2006;70:1249-55.
[PUBMED](#) | [CROSSREF](#)
70. Ueshima H, Sekikawa A, Miura K, et al. Cardiovascular disease and risk factors in Asia: a selected review. *Circulation* 2008;118:2702-9.
[PUBMED](#) | [CROSSREF](#)
71. McPherson R, Pertsemlidis A, Kavaslar N, et al. A common allele on chromosome 9 associated with coronary heart disease. *Science* 2007;316:1488-91.
[PUBMED](#) | [CROSSREF](#)
72. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. *Science* 2007;316:1491-3.
[PUBMED](#) | [CROSSREF](#)
73. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. *N Engl J Med* 2007;357:443-53.
[PUBMED](#) | [CROSSREF](#)
74. Wang X, Yang B, Sun H, Zhang A. Pattern recognition approaches and computational systems tools for ultra performance liquid chromatography-mass spectrometry-based comprehensive metabolomic profiling and pathways analysis of biological data sets. *Anal Chem* 2012;84:428-39.
[PUBMED](#) | [CROSSREF](#)
75. McGarrah RW, Crown SB, Zhang GF, Shah SH, Newgard CB. Cardiovascular metabolomics. *Circ Res* 2018;122:1238-58.
[PUBMED](#) | [CROSSREF](#)
76. Shah SH, Newgard CB. Integrated metabolomics and genomics: systems approaches to biomarkers and mechanisms of cardiovascular disease. *Circ Cardiovasc Genet* 2015;8:410-9.
[PUBMED](#) | [CROSSREF](#)
77. Sun H, Olson KC, Gao C, et al. Catabolic defect of branched-chain amino acids promotes heart failure. *Circulation* 2016;133:2038-49.
[PUBMED](#) | [CROSSREF](#)

78. Hunter WG, Kelly JP, McGarrah RW 3rd, Kraus WE, Shah SH. Metabolic dysfunction in heart failure: diagnostic, prognostic, and pathophysiologic insights from metabolomic profiling. *Curr Heart Fail Rep* 2016;13:119-31.
[PUBMED](#) | [CROSSREF](#)
79. Liu YT, Jia HM, Chang X, Ding G, Zhang HW, Zou ZM. The metabolic disturbances of isoproterenol induced myocardial infarction in rats based on a tissue targeted metabolomics. *Mol Biosyst* 2013;9:2823-34.
[PUBMED](#) | [CROSSREF](#)
80. Jiang M, Kang L, Wang Y, et al. A metabolomic study of cardioprotection of ginsenosides, schizandrin, and ophiopogonin D against acute myocardial infarction in rats. *BMC Complement Altern Med* 2014;14:350.
[PUBMED](#) | [CROSSREF](#)
81. Park JY, Lee SH, Shin MJ, Hwang GS. Alteration in metabolic signature and lipid metabolism in patients with angina pectoris and myocardial infarction. *PLoS One* 2015;10:e0135228.
[PUBMED](#) | [CROSSREF](#)
82. Zhu M, Han Y, Zhang Y, et al. Metabolomics study of the biochemical changes in the plasma of myocardial infarction patients. *Front Physiol* 2018;9:1017.
[PUBMED](#) | [CROSSREF](#)
83. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol* 2003;32:1-22.
[PUBMED](#) | [CROSSREF](#)
84. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol* 2015;44:512-25.
[PUBMED](#) | [CROSSREF](#)
85. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol* 2016;40:304-14.
[PUBMED](#) | [CROSSREF](#)
86. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol* 2017;46:1985-98.
[PUBMED](#) | [CROSSREF](#)
87. Bowden J, Spiller W, Del Greco M F, et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression. *Int J Epidemiol* 2018;47:2100.
[PUBMED](#) | [CROSSREF](#)
88. Zhao Q, Wang J, Spiller W, Bowden J, Small DS. Two-sample instrumental variable analyses using heterogeneous samples. *Stat Sci* 2019;34:317-33.
[CROSSREF](#)
89. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. *Stat Methods Med Res* 2017;26:2333-55.
[PUBMED](#) | [CROSSREF](#)
90. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. *Int J Epidemiol* 2019;48:713-27.
[PUBMED](#) | [CROSSREF](#)
91. von Hinke S, Davey Smith G, Lawlor DA, Propper C, Windmeijer F. Genetic markers as instrumental variables. *J Health Econ* 2016;45:131-48.
[PUBMED](#) | [CROSSREF](#)
92. Davies NM, von Hinke Kessler Scholder S, Farbmacher H, Burgess S, Windmeijer F, Smith GD. The many weak instruments problem and Mendelian randomization. *Stat Med* 2015;34:454-68.
[PUBMED](#) | [CROSSREF](#)
93. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I² statistic. *Int J Epidemiol* 2016;45:1961-74.
[PUBMED](#) | [CROSSREF](#)
94. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol* 2013;37:658-65.
[PUBMED](#) | [CROSSREF](#)
95. Spiller W, Slichter D, Bowden J, Davey Smith G. Detecting and correcting for bias in Mendelian randomization analyses using gene-by-environment interactions. *Int J Epidemiol* 2019;48:702-12.
[PUBMED](#) | [CROSSREF](#)
96. Staley JR, Burgess S. Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. *Genet Epidemiol* 2017;41:341-52.
[PUBMED](#) | [CROSSREF](#)

97. Pikula A, Beiser AS, Wang J, et al. Lipid and lipoprotein measurements and the risk of ischemic vascular events: Framingham Study. *Neurology* 2015;84:472-9.
[PUBMED](#) | [CROSSREF](#)
98. Sun L, Clarke R, Bennett D, et al. Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults. *Nat Med* 2019;25:569-74.
[PUBMED](#) | [CROSSREF](#)
99. Valdes-Marquez E, Parish S, Clarke R, et al. Relative effects of LDL-C on ischemic stroke and coronary disease: a Mendelian randomization study. *Neurology* 2019;92:e1176-87.
[PUBMED](#) | [CROSSREF](#)
100. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. *J Am Coll Cardiol* 2012;60:2631-9.
[PUBMED](#) | [CROSSREF](#)
101. White J, Swerdlow DI, Preiss D, et al. Association of lipid fractions with risks for coronary artery disease and diabetes. *JAMA Cardiol* 2016;1:692-9.
[PUBMED](#) | [CROSSREF](#)
102. Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. *Eur Heart J* 2015;36:539-50.
[PUBMED](#) | [CROSSREF](#)
103. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. *Lancet* 2012;380:572-80.
[PUBMED](#) | [CROSSREF](#)
104. Haase CL, Tybjærg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. *J Clin Endocrinol Metab* 2012;97:E248-56.
[PUBMED](#) | [CROSSREF](#)
105. Burgess S, Freitag DF, Khan H, Gorman DN, Thompson SG. Using multivariable Mendelian randomization to disentangle the causal effects of lipid fractions. *PLoS One* 2014;9:e108891.
[PUBMED](#) | [CROSSREF](#)
106. Burgess S, Harshfield E. Mendelian randomization to assess causal effects of blood lipids on coronary heart disease: lessons from the past and applications to the future. *Curr Opin Endocrinol Diabetes Obes* 2016;23:124-30.
[PUBMED](#) | [CROSSREF](#)
107. Christensen AI, Nordestgaard BG, Tolstrup JS. Alcohol intake and risk of ischemic and haemorrhagic stroke: results from a Mendelian randomisation study. *J Stroke* 2018;20:218-27.
[PUBMED](#) | [CROSSREF](#)
108. Cho Y, Shin SY, Won S, Relton CL, Davey Smith G, Shin MJ. Alcohol intake and cardiovascular risk factors: a Mendelian randomisation study. *Sci Rep* 2015;5:18422.
[PUBMED](#) | [CROSSREF](#)
109. Holmes MV, Dale CE, Zuccolo L, et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. *BMJ* 2014;349:g4164.
[PUBMED](#) | [CROSSREF](#)
110. Chen L, Smith GD, Harbord RM, Lewis SJ. Alcohol intake and blood pressure: a systematic review implementing a Mendelian randomization approach. *PLoS Med* 2008;5:e52.
[PUBMED](#) | [CROSSREF](#)
111. Jee YH, Jung KJ, Park YB, Spiller W, Jee SH. Causal effect of alcohol consumption on hyperuricemia using a Mendelian randomization design. *Int J Rheum Dis*. 2019 [Epub ahead of print].
[PUBMED](#) | [CROSSREF](#)
112. Frayling TM, Stoneman CE. Mendelian randomisation in type 2 diabetes and coronary artery disease. *Curr Opin Genet Dev* 2018;50:111-20.
[PUBMED](#) | [CROSSREF](#)
113. Zhang X, Lv WQ, Qiu B, et al. Assessing causal estimates of the association of obesity-related traits with coronary artery disease using a Mendelian randomization approach. *Sci Rep* 2018;8:7146.
[PUBMED](#) | [CROSSREF](#)
114. Geng T, Smith CE, Li C, Huang T. Childhood BMI and adult type 2 diabetes, coronary artery diseases, chronic kidney disease, and cardiometabolic traits: a Mendelian randomization analysis. *Diabetes Care* 2018;41:1089-96.
[PUBMED](#) | [CROSSREF](#)
115. Lyall DM, Celis-Morales C, Ward J, et al. Association of body mass index with cardiometabolic disease in the UK Biobank: a Mendelian randomization study. *JAMA Cardiol* 2017;2:882-9.
[PUBMED](#) | [CROSSREF](#)

116. Hägg S, Fall T, Ploner A, et al. Adiposity as a cause of cardiovascular disease: a Mendelian randomization study. *Int J Epidemiol* 2015;44:578-86.
[PUBMED](#) | [CROSSREF](#)
117. Emdin CA, Khera AV, Natarajan P, et al. Genetic association of waist-to-hip ratio with cardiometabolic traits, type 2 diabetes, and coronary heart disease. *JAMA* 2017;317:626-34.
[PUBMED](#) | [CROSSREF](#)
118. Xu L, Borges MC, Hemani G, Lawlor DA. The role of glycaemic and lipid risk factors in mediating the effect of BMI on coronary heart disease: a two-step, two-sample Mendelian randomisation study. *Diabetologia* 2017;60:2210-20.
[PUBMED](#) | [CROSSREF](#)
119. Dale CE, Fatemifar G, Palmer TM, et al. Causal associations of adiposity and body fat distribution with coronary heart disease, stroke subtypes, and type 2 diabetes mellitus: a Mendelian randomization analysis. *Circulation* 2017;135:2373-88.
[PUBMED](#) | [CROSSREF](#)
120. Holmes MV, Lange LA, Palmer T, et al. Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. *Am J Hum Genet* 2014;94:198-208.
[PUBMED](#) | [CROSSREF](#)
121. Ligthart S, de Vries PS, Uitterlinden AG, et al. Pleiotropy among common genetic loci identified for cardiometabolic disorders and C-reactive protein. *PLoS One* 2015;10:e0118859.
[PUBMED](#) | [CROSSREF](#)
122. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC), Wensley F, Gao P, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. *BMJ* 2011;342:d548.
[PUBMED](#) | [CROSSREF](#)
123. Casas JP, Shah T, Cooper J, et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. *Int J Epidemiol* 2006;35:922-31.
[PUBMED](#) | [CROSSREF](#)
124. Kardys I, de Maat MP, Uitterlinden AG, Hofman A, Witteman JC. C-reactive protein gene haplotypes and risk of coronary heart disease: the Rotterdam Study. *Eur Heart J* 2006;27:1331-7.
[PUBMED](#) | [CROSSREF](#)
125. Ross S, D'Mello M, Anand SS, et al. Effect of bile acid sequestrants on the risk of cardiovascular events: a Mendelian randomization analysis. *Circ Cardiovasc Genet* 2015;8:618-27.
[PUBMED](#) | [CROSSREF](#)
126. Ahmad OS, Morris JA, Mujammami M, et al. A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease. *Nat Commun* 2015;6:7060.
[PUBMED](#) | [CROSSREF](#)
127. Larsson SC, Scott RA, Traylor M, et al. Type 2 diabetes, glucose, insulin, BMI, and ischemic stroke subtypes: Mendelian randomization study. *Neurology* 2017;89:454-60.
[PUBMED](#) | [CROSSREF](#)
128. Davey Smith G. Does schizophrenia influence cannabis use? How to report the influence of disease liability on outcomes in Mendelian randomization studies. TARG Blog [Internet]. Bristol: University of Bristol; 2019 [cited 2019]. Available from <https://targ.blogs.bristol.ac.uk/2019/01/07/>.
129. Lieb W, Jansen H, Loley C, et al. Genetic predisposition to higher blood pressure increases coronary artery disease risk. *Hypertension* 2013;61:995-1001.
[PUBMED](#) | [CROSSREF](#)
130. Åsvold BO, Bjørngaard JH, Carlslake D, et al. Causal associations of tobacco smoking with cardiovascular risk factors: a Mendelian randomization analysis of the HUNT Study in Norway. *Int J Epidemiol* 2014;43:1458-70.
[PUBMED](#) | [CROSSREF](#)
131. Wade KH, Richmond RC, Davey Smith G. Physical activity and longevity: how to move closer to causal inference. *Br J Sports Med* 2018;52:890-1.
[PUBMED](#) | [CROSSREF](#)
132. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N Engl J Med* 2006;354:1264-72.
[PUBMED](#) | [CROSSREF](#)
133. Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. *N Engl J Med* 2016;375:2144-53.
[PUBMED](#) | [CROSSREF](#)

134. Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of PCSK9 inhibitors. *J Am Coll Cardiol* 2018;72:314-29.
[PUBMED](#) | [CROSSREF](#)
135. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms *VKORC1*, *CYP2C9*, and *CYP4F2* as principal genetic determinants of warfarin dose. *PLoS Genet* 2009;5:e1000433.
[PUBMED](#) | [CROSSREF](#)
136. Cha PC, Mushirola T, Takahashi A, et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. *Hum Mol Genet* 2010;19:4735-44.
[PUBMED](#) | [CROSSREF](#)
137. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. *Lancet* 2013;382:790-6.
[PUBMED](#) | [CROSSREF](#)
138. Burgess S, Ference BA, Staley JR, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. *JAMA Cardiol* 2018;3:619-27.
[PUBMED](#) | [CROSSREF](#)
139. AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med* 2011;365:2255-67.
[PUBMED](#) | [CROSSREF](#)
140. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. *N Engl J Med* 2014;371:203-12.
[PUBMED](#) | [CROSSREF](#)
141. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med* 2017;376:1713-22.
[PUBMED](#) | [CROSSREF](#)
142. Carter AR, Gill D, Davies NM, et al. Understanding the consequences of education inequality on cardiovascular disease: mendelian randomisation study. *BMJ* 2019;365:l1855.
[PUBMED](#) | [CROSSREF](#)